Public Release: 

Insilico to present latest advances in Machine Learning & Artificial Intelligence for drug discovery

InSilico Medicine, Inc.


IMAGE: Polina Mamoshina, Senior Research Scientist, Pharma.AI Division of Insilico Medicine, will present at the Advanced Machine Learning and Artificial Intelligence for Drug Discovery & Development Conference, June 19, 2018, in... view more 

Credit: Insilico Medicine

Monday, June 18, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research,announces the presentation of Polina Mamoshina, Sr Research Scientist in Pharma.AI Division of Insilico Medicine, at the Advanced Machine Learning and Artificial Intelligence for Drug Discovery & Development Conference, organized by BIS Group.

Mamoshina's talk "Deep Learning for Drug Discovery: Applying Deep Adversarial Networks for New Molecule Development" will be devoted to the recent advances of Artificial Intelligence in drug discovery processes. The presentation will focus on the application of Generative Adversarial Networks (GANs) for generation of novel small organic molecules with the desired set of pharmacological properties.

"I am very pleased to speak alongside the thought leaders in the industry at the Advanced Machine Learning and Artificial Intelligence for Drug Discovery & Development Conference. The event brings together key experts to discuss the impact of Artificial Intelligence on drug discovery. Technologies based on AI tend to substantially change drug discovery process accelerating it and introducing a set of highly promising leads instead of thousands molecules with unknown activities. Possibly, the applications of AI in drug discovery could increase the drug space allowing us to find new drugs, new mechanisms of action and even new chemistry", said Polina Mamoshina, Senior Research Scientist in Insilico Medicine, Inc.

"We are very happy to present at the Advanced Machine Learning and Artificial Intelligence for Drug Discovery & Development Conference, which gathers many thought leaders in AI. The topic of AI for drug discovery is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.


BIS Group is a Business Intelligence Services company supporting innovative and forward thinking companies in Oil & Gas, Energy, Construction, Telecommunications, Pharmaceutical, Management and Financial Services. The organizers of Advanced Machine Learning and Artificial Intelligence for Drug Discovery & Development Conference aim to discuss how AI & machine learning can help to exceed the existing approach in drug discovery and development and accelerate drug discovery. The event will be held on June 19-20.

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD


Official Conference Website:

About Insilico Medicine, Inc

Insilico Medicine, Inc. is developing the next-generation artificial intelligence for the integrated end-to-end pharmaceutical biomarker development, target identification, small molecule generation and prediction of the clinical trials outcomes. Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI. Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named the one of the global top 100 AI companies by CB Insights. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.